Aro Biotherapeutics is a biotechnology company based in Philadelphia, pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is focused on developing a pipeline of Centyrin-based therapeutic candidates and working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

Susan Dillon

Karyn O’Neil

Aro Biotherapeutics

Unlocking the Potential of Genetic Medicines

Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.

Johnson & Johnson Robotics and Digital Solutions

Ridgeback Capital

BioMotiv

Biotechnology Value Fund

BVF Partners

HealthCap

Ionis Pharmaceuticals

Northpond Ventures

Cowen Healthcare Investments

Johnson & Johnson Innovation – JJDC

We are excited for the opportunity to present at the 20th Annual WORLD Symposium 2024 meeting!

We are excited to announce we have secured our Series B financing!

https://lnkd.in/d_znquZc

We are excited to announce our transition to a clinical stage company with the start of our first in human trial of ABX1100, a Centyrin-siRNA conjugate in development for Pompe Disease

#Centyrin #siRNA #PompeDisease #RareDisease

https://lnkd.in/erdkqrKz

Metric
Company Name	Aro Biotherapeutics
Symbol
MSH ID	COM:AROBIOTX
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	44
Website	arobiotx.com
LinkedIn	aro-biotherapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:AROBIOTX

Aro Biotherapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue